- Home
- ECOR vs ACRV Comparison
ECOR vs ACRV Comparison
Compare ECOR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- ACRV
- Stock Information
- Founded
- ECOR 2005
- ACRV 2018
- Country
- ECOR United States
- ACRV United States
- Employees
- ECOR N/A
- ACRV N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ECOR Health Care
- ACRV Health Care
- Exchange
- ECOR Nasdaq
- ACRV Nasdaq
- Market Cap
- ECOR 39.7M
- ACRV 41.7M
- IPO Year
- ECOR 2018
- ACRV 2022
- Fundamental
- Price
- ECOR $5.37
- ACRV $1.39
- Analyst Decision
- ECOR Strong Buy
- ACRV Buy
- Analyst Count
- ECOR 2
- ACRV 7
- Target Price
- ECOR $25.50
- ACRV $17.40
- AVG Volume (30 Days)
- ECOR 118.5K
- ACRV 248.0K
- Earning Date
- ECOR 08-06-2025
- ACRV 08-13-2025
- Dividend Yield
- ECOR N/A
- ACRV N/A
- EPS Growth
- ECOR N/A
- ACRV N/A
- EPS
- ECOR N/A
- ACRV N/A
- Revenue
- ECOR $27,700,000.00
- ACRV N/A
- Revenue This Year
- ECOR $23.21
- ACRV N/A
- Revenue Next Year
- ECOR $44.10
- ACRV $1,037.93
- P/E Ratio
- ECOR N/A
- ACRV N/A
- Revenue Growth
- ECOR 30.16
- ACRV N/A
- 52 Week Low
- ECOR $4.16
- ACRV $1.05
- 52 Week High
- ECOR $19.49
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- ECOR 42.75
- ACRV 57.18
- Support Level
- ECOR $4.16
- ACRV $1.20
- Resistance Level
- ECOR $5.74
- ACRV $1.32
- Average True Range (ATR)
- ECOR 0.53
- ACRV 0.09
- MACD
- ECOR -0.16
- ACRV 0.01
- Stochastic Oscillator
- ECOR 37.19
- ACRV 79.17
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.